Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTH244
- Development stage
- Preclinical
- Lead developer
- Verra Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
VTH244 is a preclinical-stage drug candidate being developed by Verra Therapeutics. It is part of the company's proprietary platform focused on peptide-based small proteins, which are designed as modified native peptide inhibitors. While specific indications and molecular targets for VTH244 have not been publicly disclosed in detail, it belongs to a pipeline that includes treatments for chronic obstructive pulmonary disease (COPD) and post-heart attack recovery (myocardial infarction). The drug is part of a portfolio of candidates aimed at addressing inflammatory and fibrotic disease pathways identified through the company's research platform.
Beyond the preview
Go deeper on VTH244.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTH244.